Idaho

The Idaho State Controller's Office adds together what covered entities reported for 2025 and prints the totals in one report. It gives statewide totals only, so no figure here belongs to any one entity. Every figure below is the state's, as printed, and links to its page of the report.

Headline figures

The report opens with four figures under its own heading, KEY HIGHLIGHTS. Where the report rounds a figure, it is shown here the way the report rounds it. The tables further down give the full amounts.

CY2025 Key Financial Metrics (All Covered Entities): the labels of the report's chart, as printed
Label as printedAmount as printed
Payments to Contract Pharmacies
Aggregate Acquisition Cost
340B Savings Utilized
Aggregate Payments Received

The report draws these four amounts as a chart, in whole dollars. The bars here are drawn to one scale: the full width is $900 million. Open the chart (Page 3 of the report PDF)

Total aggregate payments received ($812.9 million) exceed aggregate acquisition costs ($399.1 million), yielding a gross program margin of approximately $413.7 million.

For Calendar Year 2025, Idaho covered entities collectively reported nearly 1.92 million prescription drugs obtained under the 340B program and dispensed to patients, generating over $812.9 million in aggregate payments received, while directing $430.6 million in 340B savings toward charity care, community benefit programs, and services for indigent patients.

Two paragraphs of the report's summary, word for word. Open the page (Page 2 of the report PDF)

Who reported

The report says how many submissions it adds together. It does not name the entities that sent them.

For Calendar Year 2025, 62 submissions from covered entities were received.

Covered entities with child sites (physically separate, off-site outpatient facility, or clinic associated or affiliated with the covered entity) submitted their child site data in aggregate with the parent site data.

The two sentences the report prints above the table, word for word. Open the page (Page 4 of the report PDF)
Submissions as printed, 2025 data
Submission MetricCountNotes
Total submissions received62 (Total submissions received, Count, page 4 of the report PDF)All submissions complete
Total child sites689 (Total child sites, Count, page 4 of the report PDF)
Submissions with complete status62 (Submissions with complete status, Count, page 4 of the report PDF) (100% (Submissions with complete status, Count, page 4 of the report PDF))Full compliance

Totals by payer type

The report splits four totals by who paid. Each table is shown as printed, under the report's own heading. In each table the bars are drawn to one scale: the full width is the table's TOTAL row.

Aggregate Acquisition Cost

For CY2025, the total aggregate acquisition cost across all Idaho covered entities was $399,146,308.13.

The sentence the report prints above the table, word for word. Open the page (Page 5 of the report PDF)

Aggregate Payments Received

For CY2025, the total aggregate payments received by all Idaho 340B covered entities was $812,855,944.90.

The sentence the report prints above the table, word for word. Open the page (Page 5 of the report PDF)

Aggregate Payments to Contract Pharmacies

For CY2025, Idaho covered entities made total aggregate payments to contract pharmacies of $46,157,188.85.

The sentence the report prints above the table, word for word. Open the page (Page 6 of the report PDF)

Number of Claims by Payer Type

For CY2025, Idaho covered entities collectively reported 1,916,995 total claims across all payer categories.

Commercial insurance was the dominant payer category, accounting for 45.4% of all claims, followed by Medicare at 31.1%.

The two sentences the report prints above the table, word for word. Open the page (Page 6 of the report PDF)

Use of savings

The report's last table gives the amount of 340B savings applied to each use, as printed. The names of the uses are the report's own words.

340B Savings Utilization

For CY2025, Idaho covered entities directed a total of $430,646,950.35 in 340B savings.

The sentence the report prints above the table, word for word. Open the page (Page 7 of the report PDF)
340B Savings Utilization as printed, 2025 data
Savings Use CategoryAmount Applied% of Total Savings
Offset financial loss due to under-reimbursement from government programs41.8% (Offset financial loss due to under-reimbursement from government programs, % of Total Savings, page 7 of the report PDF)
Offset financial loss due to providing uncompensated care14.2% (Offset financial loss due to providing uncompensated care, % of Total Savings, page 7 of the report PDF)
Financial assistance for patients who cannot pay for care or medications10.4% (Financial assistance for patients who cannot pay for care or medications, % of Total Savings, page 7 of the report PDF)
Prescription medication assistance programs3.8% (Prescription medication assistance programs, % of Total Savings, page 7 of the report PDF)
Community health programs and outreach/education2.2% (Community health programs and outreach/education, % of Total Savings, page 7 of the report PDF)
Subsidized health services provided below actual cost2.1% (Subsidized health services provided below actual cost, % of Total Savings, page 7 of the report PDF)
Education of health professionals serving underserved populations1.1% (Education of health professionals serving underserved populations, % of Total Savings, page 7 of the report PDF)
Programs addressing barriers to healthcare access0.4% (Programs addressing barriers to healthcare access, % of Total Savings, page 7 of the report PDF)
Additional / Other reported uses (10 entities*)24.0% (Additional / Other reported uses (10 entities*), % of Total Savings, page 7 of the report PDF)
TOTAL100.0% (TOTAL, % of Total Savings, page 7 of the report PDF)

*Ten entities reported Additional/Other uses of their 340B program savings. The majority of other uses were for capital improvement projects, pharmacy staff salary and benefits, 340B program administration staff necessary for program compliance, and third-party administration (TPA) costs related to participating in the 340B program. Some entities reported other use of their savings. Idaho Code § 41-351 requires this report to remain aggregated and confidential. Including these details may identify individual entities and compromise confidentiality.

The note the report prints under the table, word for word. Open the page (Page 7 of the report PDF)

The CY2025 data submitted pursuant to Idaho Code § 41-351 demonstrates that Idaho's 340B covered entities collectively process nearly 1.92 million claims, generating $812.9 million in aggregate payments received for 340B drugs from payers and patients, with an acquisition cost of $399.1 million for the drugs, and directs $430.6 million in 340B program savings toward community benefit programs.

The report's closing paragraph, word for word. Open the page (Page 7 of the report PDF)

Differences in this report

Three places where two figures of the report differ. Nothing was changed; both figures are kept as printed.

  1. The Total Claims rows added together beside the table's TOTAL row

    Expected
    1,916,602
    Printed
    1,916,995
    Difference
    393

    The six payer rows of Number of Claims by Payer Type add up to 1,916,602. The table's TOTAL row prints 1,916,995, the figure the report also prints in its Total Claims Dispensed tile and in the paragraph above the table.

    The report itself says the two figures agree. Rule claims.rows=total in Methods.

  2. The Amount Applied rows added together beside the table's TOTAL row

    Expected
    430,646,947.35
    Printed
    430,646,950.35
    Difference
    3.00

    The nine rows of 340B Savings Utilization add up to 430,646,947.35. The table's TOTAL row prints 430,646,950.35, the figure the report also prints in the paragraph above the table.

    The report itself says the two figures agree. Rule savings_use.rows=total in Methods.

  3. The TOTAL row of 340B Savings Utilization beside the TOTAL row of Aggregate Payments Received minus the TOTAL row of Aggregate Acquisition Cost (the difference the report's summary calls the gross program margin)

    Expected
    413,709,636.77
    Printed
    430,646,950.35
    Difference
    16,937,313.58

    The report does not say these two figures agree; they are shown side by side. Its summary describes payments received less acquisition cost as a gross program margin of approximately $413.7 million; the two TOTAL rows give 812,855,944.90 minus 399,146,308.13, which is 413,709,636.77. The TOTAL row of 340B Savings Utilization prints 430,646,950.35.

    The report does not say the two figures agree. They describe related things and are shown together. Rule savings_use.total=payments_received.total-acquisition_cost.total in Methods.

Read it with care. These are totals the state published. They are not what any one entity filed, and no figure here can be traced to an entity. The entities' own filings are not in this dataset, so the totals cannot be checked against them.

No measure is calculated for Idaho. The other states' measures are worked out for each filer, and this report has one set of figures for the whole state. So Idaho's figures are shown as the state printed them, and the states are not added together or compared. Methods sets out each calculation.

Where the figures come from

Idaho's law has covered entities report by April 1 each year and keeps those filings confidential. Before November 15 each year the State Controller publishes a report of the figures added together. What is public is that report.

Report PDF
Open the report on the Idaho State Controller's Office file store
Title
Idaho 340B Drug Pricing Program, Inaugural Report, Calendar Year 2025
Period
January 1 through December 31, 2025 (Calendar Year 2025)
SHA-256
ec161332907f5abccbe4cc36ce2abf0bbb5c453cde87a43630288c528856b0b8
Retrieved
15 November 2026
Pages used
2 to 7 of 7